When COVID-19 first emerged, the U.S., under President Donald Trump, made an urgent bet on vaccines — and it paid off ...

Amid a multi-year surge in vaccine misinformation sparked by the Covid-19 pandemic, social media posts claimed that the ...

Concerned that the nation’s health leadership is casting unfounded doubt on the safety of well-studied vaccines and may take ...

Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday. The news sent company shares ...

Peter Kotlár has long promoted fringe theories about mRNA vaccines, claiming they "cause the human body to produce toxins." ...

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

A middle school student north of Dallas has tested positive. Meanwhile, Illinois has confirmed its first case in the state. Plus: A study in mice shows that covid is still contagious a week or more ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $28.00. The ...

Novavax’s vaccine, which is the only protein-based COVID-19 vaccine, is awaiting for its full approval. Once approved, it ...